A reasonable chance it could cause serious harm or death.
Particulate matter: particulate matter identified as cellulose, polystyrene, polyethylene teraphalate, stainless steel, or stopper material in the product solution.
| Brand name | ARGATROBAN |
| Generic name | ARGATROBAN |
| Active ingredient(s) | ARGATROBAN |
| Distributed by / for | Par Pharmaceutical, Chestnut Ridge, NY 10977 |
| NDC | 42023-182-01 |
| Full product label | Argatroban Injection, USP, 250 mg/2.5mL (100 mg/mL), 2.5 mL x 1 Single Dose Vial, Rx only, Manufactured for: Endo USA, Malvern,PA 19355/Argatroban Injection, 250 mg/2.5mL (100 mg/mL), 2.5 mL x 1 Single Dose Vial, Rx only, Distributed by: Par Pharmaceutical, Chestnut Ridge, NY 10977, NDC 42023-182-01. |
| Recalling firm | Par Health USA, LLC |
| Distribution | Nationwide within the United States |
| Quantity | 18,991 vials |
| Recall initiated | 2026-10-13 |
| Report date | 2026-10-28 |
| Recall completed | — |
| Recall number | D-0082-2027 |
| Classification | Class I |
| FDA status | Ongoing |
| Origin on file | Rochester MI United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗